martedì, 27 luglio 2021
Medinews
15 Novembre 2016

EC Approves Frontline Olaratumab for Soft Tissue Sarcoma

The European Commission has granted an accelerated approval to olaratumab in combination with doxorubicin as a frontline therapy for patients with advanced soft tissue sarcoma, making it the first new therapy for this indication in over 40 years.The decision, which was preceded by a positive opinion from the Committee for Medicinal Products for Human Use, was based on findings from the phase II JGDG study, which showed an 11.8-month improvement in overall survival … Leggi tutto

TORNA INDIETRO